Mar 3, 2016 - 17th International Congress on Infectious Diseases / International Journal ... Public Health Emergency of International Concern (PHEIC) related.
17th International Congress on Infectious Diseases / International Journal of Infectious Diseases 45S (2016) 1–477
13
Type: Invited Presentation
Type: Invited Presentation
Final Abstract Number: 10.004 Session: Ebola and Beyond: Preparing for the Next Pandemic Date: Thursday, March 3, 2016 Time: 15:45-17:45 Room: Hall 2
Final Abstract Number: 11.001 Session: Advances and Understanding in the Management of Drug Resistant Tuberculosis Date: Thursday, March 3, 2016 Time: 15:45-17:45 Room: Hall 5
WHO reforms and UN actions D. Lucey Georgetown University, Washington, DC, USA Abstract: This presentation will summarize five reports and commissions released between July 2014-Feb 2015 that address the response to the catastrophic Ebola epidemic in West Africa and recommend changes to prepare better for future infectious disease outbreaks, crises, and emergencies. The focus will be on World Health Organization (WHO) reforms and actions by the United Nations (UN). These reports and commissions include, but may not be limited to: (1) July 7, 2015. Report of the Ebola Interim Assessment Panel. Chaired by Dame Barbara Stocking. (2) Nov 22, 2015 published online in the Lancet. Moon S. et al. Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSTMH Independent Panel on the Global Response to Ebola. (3) Jan 13, 2016. The Neglected Dimensions of Global Security: A Framework to Counter Infectious Disease Crises. Chaired by Peter Sands. (4) Jan 18, 2016 (Second and Final Report). Advisory Group on Reform of WHO’s Work in Outbreaks and Emergencies. Chaired by Dr. David Nabarro. (5). Feb 2016 (anticipated publication): The United Nations Secretary-General’s High-Level Panel on the Global Response to Health Crises. While awaiting implementation of much-needed WHO Reform, as revealed by the Ebola catastrophe in West Africa, the emerging pandemic of Zika virus, and possibly-related microcephaly, was recognized. Lucey and Gostin. The Emerging Zika Pandemic: Enhancing Preparedness. JAMA published online (Wednesday) Jan 27, 2016 (online) called on the WHO Director-General to apply one of the most crucial lessons that should have been learned from the delayed WHO response to the Ebola epidemic in West Africa, and to no longer delay convening the WHO Emergency Committee to advise whether to declare a Public Health Emergency of International Concern (PHEIC) related to the Zika virus crises and to provide global guidance and leadership accordingly. http://dx.doi.org/10.1016/j.ijid.2016.02.062
Diagnostic advances in assessing drug resistant tuberculosis C. Rodrigues P. D. Hinduja National Hospital & Medical Research Centre, Mumbai, India Abstract: (no abstract received from presenter) http://dx.doi.org/10.1016/j.ijid.2016.02.063 Type: Invited Presentation
Final Abstract Number: 11.002 Session: Advances and Understanding in the Management of Drug Resistant Tuberculosis Date: Thursday, March 3, 2016 Time: 15:45-17:45 Room: Hall 5
Translating genomics research into control of MDR tuberculosis: Lessons learned and future prospects M.P. Nicol University of Cape Town, Cape Town, South Africa Abstract: The global MDR-TB caseload is increasingly driven by primary transmission of MDR-TB in high burden countries. Control will require interruption of transmission through earlier detection, effective outbreak investigation, detailed resistance testing to guide tailored treatment for patients with highly resistant TB and development and rapid access to better drugs. Genomics research and the application of technologies enabled through genomic research and technological innovation can play a critical role in each of these areas. Early diagnosis is facilitated through rapid and sensitive molecular detection of resistance-conferring mutations, real-time whole genome sequencing is now being used to target outbreak investigation and to rapidly identify resistance to second-line drugs and drug development has been enabled through the development of sophisticated screening methods supported by genomic tools. However, the promise of the genomic revolution has not yet been translated to more effective control of MDR-TB, and significant obstacles and gaps in knowledge remain. This presentation will highlight recent advances in this area, describe where existing genomic technologies are already being applied in MDR-TB programmes and identify key knowledge gaps that remain. http://dx.doi.org/10.1016/j.ijid.2016.02.064
